Abstract  by unknown
J A C CFebmary 1997 ABSTRACTS - Poster 487A
11076-591 CornparisonofMonotherapyforReductionof Left
AtrialSizelnMffd-to-ModarataHypsrtenaion:
Resultsofa MulticanterTrial
J.S. Gottdiener, D. Williams, D. Reda, B. Materson for the VA Cooperative
Study Group on Anfi-Hyperfensive Agents. Geo@etowmUrriversityHospik/,
WashingtonDC, USA
WhileLVmass and left atrial (LA) size are both increased in hypertension
(HTN) and are both predictors of clinical outcome, few data are available
on the effects of treatment on LA size. We report rasults of a 15 center
randomized double-blind dose-titration trial of six active drugs on LA size. In
587men (av BP 152 + 14/99+3 mmHg, av age 58 + 10 yrs, av LA siza 41
+ 6 mm, range 20-63 mm) centrally read echos were compared between
atenolol (ATEN), captopril (CAPT), clonidine (CLON), diltiezem (DILT), hy-
droshlomthiazide (HCTZ) and prazbsin (PRAZ). With HCTZ change In IA
size from beseline was -1.3 + 5.4 mm at 8 wks (p = 0.053), –2.7 + 4.8
mm at one yr (p = 0.002), and –5.7 + 7.3 at two yrs (p = 0.001). Decrease
in LA size with HCTZ differed at one yr from all other drugs (p = 0.004
ANOVA) although reductions (p < 0.05) of LV mass occurred with HCTZ,
ATEN and CAPT in the highest tersile. Predictors of change in LA size on
mixed model multivarlate analyaiswere dmg (p < 0.0001), treatment duration
(p< 0.0001), baseline LA size (p -=0.0001), age (p = 0.018), body weight (p
< 0,0001) and LV cavity size (p = 0.011), but not ayatolic BP, race, aodium
excretion, or physical activity.
Conclusion:Despite equivalent reduction of diastolic BP with 6 active
drugs, only HCTZ was associated with early and sustained reduction of LA
size.
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HypertrophicHaart
Franco Sau, Crisotemide Seguro, Raffaele Congiu, Benedetta Guaita,
Angelo Cherchi. hrstitute of CardiologyUrriversityof Cag/iwl /k#y
The aim of our study was to evaluate the effect of long-term antihypsrten-
sivatherapy (HT) cmstructure of non hyperfrophic left ventricle. Thirty-seven
hypertensive pts (mean age 43 years), without LV hypertrophy et echocar-
diography (LVmass <140 @mzin men and g/m2 Inwomen), were studied by
setial olinisal aohooardiographic exams during 12 months of HT. The were
divided in two subgroups on the base of LV geometry: 23 pts had normal LV
geometry, that is a normal ratio between wail thickness and ventricular cavity
(h/R s 0.43) and 14 pts had LV concentric remodeling that is an increased
relative wall thickneas (tVR z 0.43). Blood pressure decreased significantly
after 1 month and showad a progressive dacraase until the end of the study in
both subgroups. LVend-diastolic dimension (EDD), septal (ST) and posterior
wali thickness (PWT), LV mass and h/R ratio did not significantly change in
pts with normai LV geometry throughout the study. In pts with LV concentric
remodeling LV increased significantly after 3 months, ST decreased after 3
months (baseiine: 12.3+ 1.6 mm; after 12 months 11.1+ 1.8 mm, ps 0.001
); LV PWT deoreased after 6 months (baseline: 10.0 + 1.0 mm; after 12
months: 9.2 4=1.4 ps 0.01); LV mass decreased after 9 months (be$eiine:
122 + 16 g/m2; after 12 months: 112 + 14 @m* ps 0.001 ); hJRratio de-
creased after 1 month (baseline: 0.50+ 0.05; after 12 months: 0.44+ 0.07,
p s 0.001). LV geometty’ normalized in 7 of these pts (50%) at the end of
anti-HT.
In conclusion, anti-HT does not seem to be able to decrease LV mass in
hypertensive pts with non hypertrophic heart and normal ventricular geome-
try. It ia, however, able to decrease LV mass and to improve LV geomet~ in
pts with T.Vconcentric remodeling
m107661 Effectsof Picotamide,anAntiplateletDrug,onUrinawThromboxane/ProatecvclinMetabolizes
andBfkodPressurein Hypknsive Patients
TreatedWithanACE-inhibitor
M. Milani, G. Abbiati L. Arrigoni. MedicalDepartment,SwrdozI% Milan,
/ta/y1PharmacologyDapartrnerrt,SarrdozPE Milan,Italy
Concomitant treatment with aspirin and others cyclooxygenase inhibitors
(CO-1)could partiailybufferthe blind pressure (BP) lowering effectsofantihy-
pattensive drugs, particularityACE-inhibitors (ACE-l). This interaction could
be due to tha block of vasodilating prostaglandins production. Picotamide
(Pioo) is a non-CO-1antiplatelet drug which, in vitro, inhibits thromboxane
(Tx) synthase and antagonizes Tx receptors, without affeoting prostacyclin
(PG12)production. We asaessed the effeota of Pico, 600 mg twice daily, on:
1) urinary excretion of ll-dehydm(DH)-TxB2, the main platelet Txmetabolite,
and 6-keto-PGFla, the main metabolizeof PG12,and 2) casual BP valuas in
hypertensive (HT) patients treated with the ACE-i enalaprfl. Tweive HT pa-
tients, under chronic treatment with enalapril 20 mg daiiy, (8 men; mean age
54+ 4 years) were enroiied in a doubie-blind, placebo-controlled, cross-over
8-week trial. Urinary excretion (24-hour urine collection) of 11-DH-TxB2 and
6-keto-PGFla (pg) were measured at base-line and at the end of each cross-
over phase, by means of RIA test (NEN Research Boston MA). Base-line
11-DH-TxB2and 6-keto-PGFla were 58 and 45 p~~mol creatinine (cr) re-
spectively. Pico reduced 11-DH-TxB2by 40%, (31 pg/~mol cr; P c 0.05) as
compared to base-lineand placebo (53 pg/pmol cr) values. Pico did not affect
the excretion of 6-kato-PGFlu (base-iine: 45 pg; piacebo: 46 pg; Pico: 43
P9).Base-linesyatolic (SBp) and diastolic (DBP) values were 14s/85 mm Hg.
Affer Picoand placetm treatments, SBP/DBPvalues were 147/64 and 148/83
mmHg, respecflveiy (NS). In HT patients treated with enalapril, Pico exerts an
antipiatelet effect, without interfering with the BP lowering action of the ACE-I.
~1076-621EarlyLefiventricu,arMassRegressionMeeaured
by3D Echocardiographyin Hypertensive
SubjectsisAssociatedwithImprovementof
Doppler-MeasuredMitralInflow
A.S. Gopal, Z. Shen, 0.0. Akinboboye, A.M. Keller, D.L. King. MowrtSinai
MedicalCenterandColumbiaUniversityNewyo&, NY LISA
Background:Measurement of changes in diastolic funotlon indicated by mi-
tral inflow velocity Is usefui for assessing the efficacy of antihypertensive
therapy. We have previously demonstrated by three-dlmensionai oohooar-
diography (3D ECHO) a significant reduction of ieft ventricular (LV) mass
early (6 weeks) after initiation of antihypertensive therapy. Howevar, there is
Iittie data to indicate if Doppler-derived mitral Infiow parameters of diastoiic
function also show significant changes atthisearly atageoftherapy. Purpose:
Todetermine if Doppler-derived mitral inflow parameters show improvement
after 6 weeks of therapy paralleling reduction of LV mass. Methods: 20 pa-
tients with uncontrolled hypertension and hyperfrophy underwent 3D ECHO
and Doppler assessment of mitral inflow at baseline and after 6 weeka of
therapy. LV mass was compufed by a 3D ECHO surface reconstruction al-
gorithm using 8-10 short-axis images guided by an acoustic spatial bcator
and line of intersection dispiay. Doppler parameters (WA velocity ratio and
deceleration time DT) were measured at the tips of the valve leaflets. Sta-
tistica/Ana/ysis:The paired T test was usad to determine significant change
of parameters. ResrJ/ts:12 patients with initial WA ratio < 1 were found to
have significant improvement of E/A ratio from 0.678 to 0.838 after 6 weeks
(P= 0.001). DWeleration time (DT) did not show a significant change. These
12 patients alao showad a decrease of LV mass after 6 weeks (p= 0.067)
from a mean of 146.4 g to 134.2 g (14.2 g decrease). For the whole group of
20 patiants (including initially normai/pseudonormal E/A), the WA ratio also
showed significant improvement after 6 weeks from 0.909 to 1.052 (p= 0.01).
For the whole group, mean mass decreased 11.6g (p = 0.0018). Conclusion:
The Doppier-derived E/A ratio of mitral inflow velocity improvas significantly
after 6 weeks of antihypertei:sive therapy in parailei with significant reduction
of LV mass.
[ 1076-63/ Persistenceof LeftVentricularHypertropttyisa
StrongerIndicaforofCardiovascularEventsThan
BaselineLVMasaor Performance.A TenYears
Follow-Up
M.L, Muieaan, M. Saivetfi, R. Zulli, M. Castellano, D. Rizzoni, A. Cinelii,
E. Potteri, S. Calebich, E. Agabiti-Rosei. Chairof Sameiotioee Mefodo/ogia
Medics,UnivereityofE?rescia,Italy
Left ventricular hypettrophy (LVH) and reduced LV performance have bean
shown to be associated to an adverse prognosis in hypertensive patients
(Hpts); however,whether the increased cardiovascular (CV) riak is related to
persistence of LVHor to iow LV performance is unknown.
In 151uncomplicated Hpts (87 M, 64 F,age range 16-70 yrs) echooerdio-
graphic evaluation of LV anatomy and function was performed and repeatad
on averaga 10 + 1 years after the initial study. Hpts were divided aooording
to the presence or absence of LVH (LV mass index, LVMi, > 134 g/m2 in
males and 110@mzin femaies) at baseline and at foilow-up.
The incidenceof non-fatalCV eventawas significantlygreaterin patienta
withoutreductionof LVMI, after adjuatingfor traditionalrisk factors (rela-
tive risk = 3.52 vs 1.36, in Hpts with persistenceand regressionof LVH
respecfiveiy,p < 0.01). Baseiineendocardial(e) and midwall(m) fractional
shortening(FS) were lower in Hpts with bothpersistenceor regressionof
LVH(Anovap <0.02 andp< 0,0001) thaninHptswithnormalLVMLLogistic
analysisshowedthatLVMIatfoliow-upandage were independentpredictors
of non fatal CV events (p < 0.001); oniy when LVMI at follow-upwas not
considered,iogisticanalysisshowedthat age, systolicBP at follow-up,and
baselinemFS (%of predictedvalue)were independentpredictorsofnon-fatai
CV events.A tendencytowarda worseevent-freesurvivalwas observedin
Hptswitha lowmFS (c 14%) (MantelCox, p = 0.06).
Our resultssuggestthatpersistenceof LVHisa strongerindicatorsof CV
riskthanbaselinelowLVperformance.
